{"prompt": "['Cara Therapeutics, Inc., CR845', 'IND 123140, SN 0072', 'Cara Therapeutics, Inc.', 'Confidential', 'Page 35 of 92', 'CR845-CLIN3103', '6.2.2', 'Exclusion Criteria', 'A patient will be excluded from the Double-blind Phase of the study if any of the', 'following criteria are met:', '1. Known noncompliance with dialysis treatment that in the opinion of the', 'Investigator would impede completion or validity of the study;', '2. Scheduled to receive a kidney transplant during the study;', '3. Known history of allergic reaction to opiates, such as hives (Note: side effects', 'related to the use of opioids, such as constipation or nausea, would not exclude', 'patients from the study);', '4. Has a concomitant disease or a history of any medical condition that, in the', 'opinion of the Investigator, could pose undue risk to the patient, impede', 'completion of the study procedures, or would compromise the validity of the', 'study measurements, including, but not limited to:', 'a. Known or suspected history of alcohol, narcotic, or other drug abuse, or', 'substance dependence within 12 months prior to screening;', 'b. Significant systolic or diastolic heart failure (eg, New York Heart', 'Association Class IV congestive heart failure [Appendix 1, Section 14.1]);', 'c.', 'Severe mental illness or cognitive impairment (eg, dementia);', 'd. Any other relevant acute or chronic medical or neuropsychiatric condition', 'within 3 months prior to screening (eg, diagnosis of encephalopathy, coma,', 'delirium);', '5. New or change of treatment received for itch including antihistamines and', 'corticosteroids (oral, IV, or topical) within 14 days prior to screening;', '6. New or change of prescription for opioids, gabapentin, or pregabalin within', '14 days prior to screening;', '7. Received another investigational drug within 30 days prior to the start of', 'screening or is planning to participate in another clinical study while enrolled in', 'this study;', '8. In the opinion of the Investigator has pruritus attributed to a cause other than', 'ESRD or its complications (eg, patients with concomitant pruritic dermatological', 'disease or cholestatic liver disease) (Note: Patients whose pruritus is attributed to', 'ESRD complications, such as hyperparathyroidism, hyperphosphatemia, anemia,', 'or the dialysis procedure or prescription may be enrolled);', '9. Has localized itch restricted to the palms of the hands;', '10. Has pruritus only during the dialysis session (by patient report);', '11. Is receiving ongoing ultraviolet B and anticipates receiving such treatment during', 'the study;', '12. Participated in a previous clinical study with CR845.', '10 September 2019', 'Version 2.2']['Cara Therapeutics, Inc., CR845', 'IND 123140, SN 0072', 'Cara Therapeutics, Inc.', 'Confidential', 'Page 36 of 92', 'CR845-CLIN3103', 'A patient will be excluded from the Open-label Extension Phase of the study if any of', 'the additional following criteria are met at the time of entry into the Open-label', 'Extension Phase:', '13. Completed the Double-blind Phase of this study but exhibited adverse events', 'during the course of the Treatment Period that may preclude continued exposure', 'to the study drug;', '14. Was noncompliant with protocol procedures during the Double-blind Phase of', 'this study which is indicative of an inability to follow protocol procedures;', '15. Has developed a concomitant disease or any medical condition that, in the opinion', 'of the Investigator, could pose undue risk to the patient, impede completion of the', 'study procedures, or would compromise the validity of the study measurements.', '6.3', 'Removal of Patients from Therapy or Assessment', '6.3.1', 'Discontinuation of Individual Patients', 'A patient may withdraw from the study at any time at his/her own request for any reason', 'without prejudice to future medical care by the physician or at the institution.', 'A patient may be withdrawn at any time due to the following reasons:', '1. At the discretion of the Investigator or the Sponsor for safety, behavioral,', 'compliance, or administrative reasons, including, but not limited to:', 'a.', 'Lost to follow-up;', 'b. Adverse event;', 'c.', 'Lack of therapeutic efficacy;', 'd. Pregnancy;', 'e. Eligibility (Inclusion/exclusion criteria);', 'f. Subject non-compliance;', 'g. Subject withdrew consent.', '2. If a patient misses 3 consecutive doses either on Week 11 or Week 12 of the', 'Double-blind Treatment Period (these patients may still be eligible for the', 'Open-label Extension Phase at the discretion of the Investigator in consultation', 'with the Sponsor).', '3. If patient misses 6 consecutive doses at any time during the Double-blind', 'Treatment Period (these patients may still be eligible for the Open-label', 'Extension Phase at the discretion of the Investigator in consultation with the', 'Sponsor).', '4. At the discretion of the Sponsor/Medical Monitor, if a patient receives a', 'prohibited concomitant medication according to Table 1.', '10 September 2019', 'Version 2.2']\n\n###\n\n", "completion": "END"}